3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
4
Withdrawn
1
Unknown
1
Terminated
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Breast Neoplasms
28
Carcinoma, Non-Small-Cell Lung
20
Triple Negative Breast Neoplasms
9
Ovarian Neoplasms
8
Lung Neoplasms
8
Uterine Cervical Neoplasms
6
Adenocarcinoma of Lung
6
Neoplasms
5
Neoplasm Metastasis
5
Esophageal Neoplasms
5
Carcinoma, Ovarian Epithelial
4
Stomach Neoplasms
3
Recurrence
3
Prostatic Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Platinum-Refractory Fallopian Tube Carcinoma
2
Pancreatic Neoplasms
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Adenocarcinoma, Bronchiolo-Alveolar
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrent High Grade Uterine Cancer
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
vandetanib
1
pembrolizumab
1
lenvatinib
1
fosbretabulin
1
fludarabine
1
combretastatin
1
aldesleukin
1
Water
1
Thyroxine
1
Thyrotropin-Releasing Hormone
1
Tea
1
Paclitaxel
1
Milk
1
Iodine-124
1
Iodine-123
1
Fluorodeoxyglucose F18
1
Drug Therapy
1
Docetaxel
1
DNA
1
Cyclophosphamide
1
Coffee
1
Carboplatin
1
Biopsy, Fine-Needle
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Thyroid Neoplasms
×
Paclitaxel
×
Clear all
NCT01701349
2014-05-01
FACT2
Mateon Therapeutics
Phase 3
Withdrawn